Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $38.25 | Total: $191.25 |
| 1 | 10 | $32.40 | Total: $324.00 |
| 1 | 25 | $27.45 | Total: $686.25 |
| 1 | 50 | $23.40 | Total: $1,170.00 |
| 1 | 100 | $20.25 | Total: $2,025.00 |
Overview
Mivebresib (ABBV-075), also known as ABBV-075, is a potent BET inhibitor (bromodomain (BRD)-containing protein) with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.
Chemical Properties
| Molecular Formula | C22H19F2N3O4S |
| Molecular Weight | 459.47 |
| CAS Numbers | 1445993-26-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O(C1=C(C=2C3=C(C(=O)N(C)C2)NC=C3)C=C(NS(CC)(=O)=O)C=C1)C4=C(F)C=C(F)C=C4 |
Storage and Handling
0C Short Term, -20C Long Term
References
Aparna Sarthy, et al. Experimental and Molecular Therapeutics. 2016, Abstract 4718.